Sökning: onr:"swepub:oai:gup.ub.gu.se/318818" >
Outcomes of relapse...
-
Harrysson, S.Karolinska Institutet,Karolinska Institute,Karolinska University Hospital
(författare)
Outcomes of relapsed/refractory diffuse large B-cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line-A population-based study of 736 patients
- Artikel/kapitelEngelska2022
Förlag, utgivningsår, omfång ...
Nummerbeteckningar
-
LIBRIS-ID:oai:gup.ub.gu.se/318818
-
https://gup.ub.gu.se/publication/318818URI
-
https://doi.org/10.1111/bjh.18197DOI
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-485652URI
-
https://lup.lub.lu.se/record/43bd9319-68ae-4360-ab09-2a86f4f35e38URI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:149386299URI
Kompletterande språkuppgifter
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Several recently published trials investigate novel therapies for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). To estimate the benefit of these therapies in the real-world setting, comprehensive data on patients treated in clinical routine are needed. We report outcomes for 736 R/R DLBCL patients identified among all curatively treated DLBCL patients in Sweden in the period 2007-2014. Survival and associations with disease characteristics, second-line treatment and fulfilment of chimaeric antigen receptor (CAR) T-cell trial criteria were assessed. Median overall survival (OS) was 6.6 months (<= 70 years 9.6 months, >70 years 4.9 months). Early relapse (<= 12 months) was strongly associated with selection of less intensive treatment and poor survival. Among patients of at most 70 years of age, 63% started intensive second-line treatment and 34% received autologous stem cell transplantation (ASCT). Two-year OS among transplanted patients was 56% (early relapse <= 12 months 40%, late relapse >12 months 66%). A minority of patients 76 years (n = 178/506, 35%) fitted CAR T trial criteria. Median progression-free survival (PFS) for patients with early relapse fitting trial criteria was 4.8 months. In conclusion, most R/R DLBCL manifest early and are often ineligible for or cannot complete intensive regimens resulting in dismal survival. Real-world patients eligible for CAR T trials also did poorly, providing a benchmark for efficacy of novel therapies.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Eloranta, S.Karolinska Institutet,Karolinska Institute,Karolinska University Hospital
(författare)
-
Ekberg, SaraKarolinska Institutet,Karolinska Institute(Swepub:lu)sa7767ek
(författare)
-
Enblad, GunillaUppsala University,Uppsala universitet,Institutionen för immunologi, genetik och patologi(Swepub:uu)gunienbl
(författare)
-
El-Galaly, T. C.Karolinska Institutet,Karolinska Institute,Aalborg University Hospital
(författare)
-
Sander, B.Karolinska Institutet
(författare)
-
Sonnevi, K.Karolinska Institutet
(författare)
-
Andersson, Per-Ola,1964Gothenburg University,Göteborgs universitet,Institutionen för medicin,Institute of Medicine,South Alvsborg Hosp, Dept Hematol, Borås, Sweden.;Gothenburg Univ, Sahlgrenska Acad, Gothenburg, Sweden.,Sahlgrenska Academy(Swepub:gu)xapert
(författare)
-
Jerkeman, MatsLund University,Lunds universitet,Medicinsk onkologi,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Lymfom - Klinisk forskning,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Onkologi övergripande,Institutionen för kliniska vetenskaper, Lund,Medical oncology,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Lymphoma - Clinical Research,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Oncology corporate,Department of Clinical Sciences, Lund(Swepub:lu)onk-mje
(författare)
-
Smedby, K. E.
(författare)
-
Karolinska InstituteKarolinska University Hospital
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:British Journal of Haematology: Wiley198:2, s. 267-2770007-10481365-2141
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Harrysson, S.
-
Eloranta, S.
-
Ekberg, Sara
-
Enblad, Gunilla
-
El-Galaly, T. C.
-
Sander, B.
-
visa fler...
-
Sonnevi, K.
-
Andersson, Per-O ...
-
Jerkeman, Mats
-
Smedby, K. E.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Hematologi
- Artiklar i publikationen
-
British Journal ...
- Av lärosätet
-
Göteborgs universitet
-
Uppsala universitet
-
Lunds universitet
-
Karolinska Institutet